Expression of CD56 is a risk factor for acute lymphocytic leukemia with central nervous system involvement in adults

References

• Surapaneni UR, Cortes JE, Thomas D, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002;94(3):773–779. doi: 10.1002/cncr.10265
   PubMed Web of Science ®Google Scholar
• Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381(9881):1943–1955. doi: 10.1016/S0140-6736(12)62187-4
   PubMed Web of Science ®Google Scholar
• Montesinos P, Diaz-Mediavilla J, Deben G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009;94(9):1242–1249. doi: 10.3324/haematol.2009.007872
   PubMed Web of Science ®Google Scholar
• Matutes E, Pickl WF, Van’t Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011;117(11):3163–3171. doi: 10.1182/blood-2010-10-314682
   PubMed Web of Science ®Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–1786.
   PubMed Web of Science ®Google Scholar
• Mi YC. [Expert consensus on adult acute lymphoblastic leukemia in China-interpretation of diagnosis and prognosis stratification]. Zhonghua Xue Ye Xue Za Zhi. 2013;34(11):994–996.
   PubMedGoogle Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526–534. doi: 10.1038/leu.2014.229
   PubMed Web of Science ®Google Scholar
• Zhang FH, Ling YW, Zhai X, et al. The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology. 2013;18(3):151–157. doi: 10.1179/1607845412Y.0000000052
   PubMed Web of Science ®Google Scholar
• Marks DI, Alonso L, Radia R. Allogeneic hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia. Hematol Oncol Clin N. 2014;28(6):995–1009. doi: 10.1016/j.hoc.2014.08.008
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543. doi: 10.1200/JCO.2010.30.1382
   PubMed Web of Science ®Google Scholar
• Matutes E, Morilla R, Farahat N, et al. Definition of acute biphenotypic leukemia. Haematologica. 1997;82(1):64–66.
   PubMed Web of Science ®Google Scholar
• Tai BC, Chen ZJ, Machin D. Estimating sample size in the presence of competing risks – cause-specific hazard or cumulative incidence approach? Stat Methods Med Res. 2015. DOI:10.1177/0962280215623107
   PubMedGoogle Scholar
• Apostolidou E, Swords R, Alvarado Y, et al. Treatment of acute lymphoblastic leukaemia: a new era. Drugs. 2007;67(15):2153–2171. doi: 10.2165/00003495-200767150-00004
   PubMed Web of Science ®Google Scholar
• Ritchey AK, Pollock BH, Lauer SJ, et al. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study. J Clin Oncol. 1999;17(12):3745–3752.
   PubMed Web of Science ®Google Scholar
• Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol. 2007;83(3):471–473. doi: 10.1016/j.yexmp.2007.08.012
   PubMed Web of Science ®Google Scholar
• Gleissner B, Goekbuget N, Rieder H, et al. CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood. 2005;106(13):4054–4056. doi: 10.1182/blood-2005-05-1866
   PubMed Web of Science ®Google Scholar
• Saikia TK, Gopal R, Nair CN, et al. Central nervous system and testicular involvement in acute lymphoblastic leukaemia. J Assoc Phys India. 1985;33(7):457–459.
   PubMedGoogle Scholar
• Paietta E, Neuberg D, Richards S, et al. Eastern Cooperative Oncology G. Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. Am J Hematol. 2001;66(3):189–196. doi: 10.1002/1096-8652(200103)66:3<189::AID-AJH1043>3.0.CO;2-A
   PubMed Web of Science ®Google Scholar
• Ito S, Ishida Y, Oyake T, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leukemia Lymphoma. 2004;45(9):1783–1789. doi: 10.1080/10428190410001683624
   PubMed Web of Science ®Google Scholar
• Sher BT, Bargatze R, Holzmann B, et al. Homing receptors and metastasis. Adv Cancer Res. 1988;51:361–390. doi: 10.1016/S0065-230X(08)60226-2
   PubMed Web of Science ®Google Scholar
• Saiki I, Fujii H, Yoneda J, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 1993;54(1):137–143. doi: 10.1002/ijc.2910540122
   PubMed Web of Science ®Google Scholar
• van der Weide M, Imandt LM, Langenhuijsen MM. Motility of leukaemic cells in acute leukaemia related to tumour mass, maturation and FAB classification. Acta Haematol. 1988;80(1):34–39. doi: 10.1159/000205595
   PubMed Web of Science ®Google Scholar
• Karimi M, Yarmohammadi H, Sabri MR. An analysis of prognostic factors and the five-year survival rate in childhood acute lymphoblastic leukemia. Med Sci Monitor. 2002;8(12):CR792–6.
   PubMedGoogle Scholar
• Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18(6):1295–1300.
   PubMed Web of Science ®Google Scholar
• Reman O, Pigneux A, Huguet F, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leukemia Res. 2008;32(11):1741–1750. doi: 10.1016/j.leukres.2008.04.011
   PubMed Web of Science ®Google Scholar